HCM HUTCHMED (China) Limited Stock Quote

HCM [NASD]

Healthcare | Drug Manufacturers - General | Hong Kong

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	0.41%	Shs Outstand	171.23M	Perf Week	3.38%
Market Cap	2.27B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	88.68M	Perf Month	44.00%
Income	-194.60M	PEG	-	EPS next Q	-	Inst Own	31.40%	Short Float	1.57%	Perf Quarter	-28.91%
Sales	356.10M	P/S	6.37	EPS this Y	-36.30%	Inst Trans	-4.64%	Short Ratio	2.17	Perf Half Y	-61.88%
Book/sh	5.76	P/B	2.34	EPS next Y	-	ROA	-20.00%	Target Price	33.86	Perf Year	-65.25%
Cash/sh	6.00	P/C	2.24	EPS next 5Y	-	ROE	-27.80%	52W Range	8.40 - 43.94	Perf YTD	-61.66%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-21.40%	52W High	-69.39%	Beta	0.95
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-	Gross Margin	27.50%	52W Low	60.02%	ATR	0.89
Employees	1759	Current Ratio	3.90	Sales Q/Q	93.60%	Oper. Margin	-58.10%	RSI (14)	63.48	Volatility	5.83% 8.13%
Optionable	Yes	Debt/Eq	0.03	EPS Q/Q	-18.30%	Profit Margin	-54.70%	Rel Volume	0.54	Prev Close	12.64
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	644.70K	Price	13.45
Recom	1.80	SMA20	21.49%	SMA50	17.93%	SMA200	-45.05%	Volume	344,929	Change	6.41%

May-04-22

Downgrade

Deutsche Bank

Buy → Hold

Sep-22-21

Downgrade

Goldman

Buy → Neutral

$46

Aug-03-21

Initiated

Jefferies

Buy

$52

Oct-02-20

Initiated

Deutsche Bank

Buy

$40

Mar-13-20

Initiated

Cantor Fitzgerald

Overweight

Feb-20-20

Initiated

Goldman

Buy

Nov-19-19

Initiated

CLSA

Buy

Oct-23-19

Reiterated

BofA/Merrill

Buy

$35 → $29

Jul-05-19

Initiated

Macquarie

Outperform

Jun-27-22 04:30AM	HUTCHMED to Announce 2022 Half-Year Financial Results GlobeNewswire
Jun-01-22 04:33AM	HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China GlobeNewswire -11.22%
May-16-22 07:00AM	Appointment of NonExecutive Director GlobeNewswire
May-15-22 07:00PM	Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases PR Newswire
May-12-22 09:54AM	Deutsche Banks Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing GlobeNewswire
May-08-22 08:30PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 GlobeNewswire
May-05-22 08:58AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 GlobeNewswire -9.53%
May-02-22 06:00AM	HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors GlobeNewswire -18.95%
Mar-31-22 12:00AM	Update on Status under Holding Foreign Companies Accountable Act GlobeNewswire
Mar-11-22 04:00AM	Update on Status under Holding Foreign Companies Accountable Act GlobeNewswire -7.52%
Mar-06-22 11:30PM	HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer GlobeNewswire
Mar-03-22 07:30AM	HUTCHMED announces retirement of CEO and appointment of new CEO GlobeNewswire -6.95%
07:00AM	HUTCHMED Reports 2021 Full Year Results and Provides Business Updates GlobeNewswire
Mar-01-22 03:30AM	HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau GlobeNewswire
Feb-10-22 03:06AM	Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMEDs ORPATHYS® for NSCLC GlobeNewswire
Feb-07-22 03:30AM	HUTCHMED to Announce 2021 Final Results GlobeNewswire
Feb-04-22 04:30AM	HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China GlobeNewswire
Jan-19-22 07:00PM	HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China GlobeNewswire
Jan-18-22 07:00PM	HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium GlobeNewswire
Jan-12-22 06:00AM	HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia GlobeNewswire
Jan-09-22 07:00PM	HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China GlobeNewswire
Dec-19-21 07:00PM	HUTCHMED Included in FTSE Russell Indexes GlobeNewswire
Dec-10-21 08:38PM	Virtus AllianzGI International Small-Cap Fund Buys Alchip Technologies, Sojitz Corp, Bystronic ... GuruFocus.com
05:00AM	HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting GlobeNewswire
Dec-05-21 07:00PM	HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer GlobeNewswire
Dec-03-21 12:00AM	HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China GlobeNewswire
Nov-23-21 07:00PM	HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy GlobeNewswire
Nov-19-21 10:59AM	Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing CNW Group
09:54AM	Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing PR Newswire
Nov-11-21 08:35AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021 PR Newswire
Nov-07-21 07:00PM	HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting GlobeNewswire
Nov-01-21 12:15AM	HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma GlobeNewswire
Oct-27-21 08:00PM	HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China GlobeNewswire
Oct-13-21 10:00AM	Hutchison China MediTech (HCM) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Oct-04-21 10:56AM	Do Hedge Funds Love HUTCHMED (China) Limited (HCM)? Insider Monkey
Sep-28-21 08:00PM	HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting GlobeNewswire
08:00PM	HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture GlobeNewswire
Sep-20-21 08:00PM	HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China GlobeNewswire
Sep-19-21 08:00PM	HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors GlobeNewswire
Sep-13-21 02:00AM	HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma GlobeNewswire
Sep-08-21 06:30AM	HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China GlobeNewswire
Sep-07-21 04:30AM	HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference GlobeNewswire -7.23%
Sep-06-21 02:00AM	HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs GlobeNewswire
Aug-25-21 08:00PM	HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer GlobeNewswire
Aug-22-21 08:00PM	HUTCHMED Selected as Constituent of Certain Hang Seng Indexes GlobeNewswire
Aug-08-21 08:00PM	HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China GlobeNewswire
08:00PM	Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China Business Wire
Jul-28-21 05:30PM	Hutchison China MediTech Ltd (HCM) Q2 2021 Earnings Call Transcript Motley Fool +14.71%
07:00AM	HUTCHMED Reports 2021 Interim Results and Provides Business Updates GlobeNewswire
Jul-27-21 08:00PM	HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer GlobeNewswire -7.20%
Jul-23-21 07:00AM	Stabilizing Actions and End of Stabilization Period in connection with the Global Offering GlobeNewswire
Jul-21-21 05:17AM	Is American Well Corporation (AMWL) A Good Stock To Buy Now? Insider Monkey
Jul-15-21 08:00PM	HUTCHMEDs Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency GlobeNewswire
Jul-14-21 08:31AM	Can the Rally in HUTCHMED (HCM) Shares Continue? Zacks
Jul-13-21 08:50AM	Here's Why "Trend" Investors Would Love Betting on Hutchison China MediTech (HCM) Zacks
02:00AM	HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca GlobeNewswire
Jul-12-21 09:52AM	HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering GlobeNewswire
Jul-05-21 07:00PM	HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China GlobeNewswire
Jul-02-21 04:30AM	HUTCHMED to Announce 2021 Half-Year Financial Results GlobeNewswire
12:57AM	The HUTCHMED (China) (LON:HCM) Share Price Is Up 189% And Shareholders Are Boasting About It Simply Wall St.
Jul-01-21 06:00AM	U.S. FDA Accepts Filing of HUTCHMEDs NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors GlobeNewswire
Jun-30-21 05:00AM	HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong GlobeNewswire +18.18%
01:03AM	China Cancer Drugmaker Surges 51% in Hong Kong Trading Debut Bloomberg
Jun-23-21 10:22AM	HUTCHMED Announces Pricing of Global Offering GlobeNewswire +15.95%
Jun-22-21 01:16PM	HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations GlobeNewswire
Jun-21-21 03:15AM	HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors PR Newswire -10.14%
Jun-18-21 11:24AM	HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors GlobeNewswire
Jun-17-21 07:30PM	HUTCHMED Launches Hong Kong Initial Public Offering GlobeNewswire
Jun-06-21 08:00PM	Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021 PR Newswire
May-20-21 02:00AM	HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program GlobeNewswire
May-17-21 02:00AM	Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors GlobeNewswire
May-07-21 07:00AM	HUTCHMED to Attend Upcoming Investor Conferences GlobeNewswire
May-04-21 03:00AM	Change of Company Name GlobeNewswire
May-03-21 07:00AM	HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors GlobeNewswire
Apr-29-21 02:00AM	HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China GlobeNewswire
Apr-22-21 08:04PM	Shareholders May Be Wary Of Increasing Hutchison China MediTech Limited's (LON:HCM) CEO Compensation Package Simply Wall St.
Apr-08-21 03:30AM	HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia GlobeNewswire
Apr-07-21 06:48AM	Moving Average Crossover Alert: Hutchison China MediTech (HCM) Zacks
Mar-29-21 02:00AM	HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies GlobeNewswire
Mar-24-21 09:30AM	HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million GlobeNewswire
03:00AM	HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors GlobeNewswire
Mar-07-21 07:32PM	Is Hutchison China MediTech (LON:HCM) Using Debt In A Risky Way? Simply Wall St.
Mar-04-21 08:30PM	Hutchison China MediTech Limited (HCM) Q4 2020 Earnings Call Transcript Motley Fool -7.16%
07:00AM	Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity GlobeNewswire
06:15AM	Hutchison China MediTech Ltd. to Host Earnings Call ACCESSWIRE
Feb-03-21 02:00AM	Chi-Med to Announce 2020 Final Results GlobeNewswire
Jan-14-21 05:00AM	Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC GlobeNewswire
Jan-10-21 08:00PM	Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases GlobeNewswire
Dec-30-20 07:00AM	Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors GlobeNewswire +6.78%
Dec-28-20 01:25PM	Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors GlobeNewswire
Dec-22-20 07:24PM	This Basket of Chinese Stocks Could Rally Over 30%, Say Analysts TipRanks
02:00AM	Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference GlobeNewswire
Nov-30-20 10:35PM	Should I Avoid Hutchison China MediTech Limited (HCM)? Insider Monkey
Nov-17-20 02:00AM	Chi-Med Announces US$100 Million Equity Investment by CPP Investments GlobeNewswire
Nov-05-20 04:00AM	Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting GlobeNewswire
Oct-30-20 08:00AM	Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences GlobeNewswire
Oct-20-20 05:03AM	How Much Is Hutchison China MediTech Limited (LON:HCM) CEO Getting Paid? Simply Wall St.
Sep-20-20 08:25AM	Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology GlobeNewswire
Sep-17-20 06:45AM	Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors GlobeNewswire
Sep-04-20 02:00AM	Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer GlobeNewswire

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience